AOD-9604

AOD-9604 corresponds to the lipolytic domain of human GH (residues 176 to 191). In preclinical models, it stimulated lipolysis in adipose tissue through a mechanism distinct from the GH receptor, possibly involving the beta-3 adrenergic receptor pathway. Unlike full-length GH, AOD-9604 did not increase IGF-1 levels, promote linear growth, or induce insulin resistance in animal models. The proposed mechanism for cartilage effects involves stimulation of proteoglycan and collagen synthesis by chondrocytes, though the receptor or signaling pathway mediating this effect has not been definitively identified.

Ng et al. (2000) demonstrated that AOD-9604 reduced body fat in obese mice without diabetogenic effects. However, the Phase 2b/3 human clinical trial (Heffernan et al., 2001) of oral AOD-9604 in obese subjects failed to demonstrate significant weight loss compared to placebo over 24 weeks. The obesity indication was abandoned. Preclinical cartilage studies (Stanton et al., 2013) showed AOD-9604 stimulated proteoglycan production in bovine and human cartilage explants, but no controlled human trials for osteoarthritis or cartilage repair have been published. The compound received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient, but this does not constitute approval for therapeutic use.

AOD-9604 is not FDA-approved for any therapeutic indication. It received GRAS status as a food ingredient in the United States, which is distinct from drug approval. Clinical development for obesity was discontinued after a failed Phase 3 trial. It is listed by WADA as a prohibited substance in sport. Current grey-market availability is primarily for injectable subcutaneous use for joint health and body composition, neither of which is supported by human clinical trial data.

No evidence-based monitoring guidelines exist. For grey-market use, clinicians may consider baseline and periodic metabolic panels (fasting glucose, insulin, lipid panel) and liver function tests. If used for joint health, clinical assessment of joint symptoms and function. IGF-1 levels are not expected to change with AOD-9604 but can confirm absence of GH-like activity.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

AOD-9604 is typically supplied as a lyophilized powder. Reconstitution with bacteriostatic water is standard practice in grey-market use. Reconstituted solutions should be refrigerated (2 to 8 degrees C). Formal stability data for injectable formulations are not publicly available. As a peptide fragment, it may be susceptible to oxidation and aggregation. Protect from light and heat.

1. 1

   RCT

   A Double-Blind, Placebo-Controlled Study of AOD9604 in Obese Subjects

   Heffernan M, Summers RJ, Thorburn A, et al. (2001). International Journal of Obesity

   Key findings: Phase 2b/3 trial of oral AOD-9604 in obese subjects failed to demonstrate statistically significant weight loss compared to placebo over 24 weeks.

   Limitations: Failed primary endpoint. Oral bioavailability may have been insufficient. Discontinued for obesity indication.

2. 2

   preclinical

   The C-Terminal Fragment of Human Growth Hormone (AOD9604) Stimulates Lipolysis Without Diabetogenic Effects

   Ng FM, Sun J, Sharma L, et al. (2000). Endocrinology

   Key findings: AOD-9604 (hGH 176-191) stimulated lipolysis in adipose tissue and reduced body fat in obese mice without the hyperglycemic or growth-promoting effects of full-length GH.

   Limitations: Animal study. Metabolic effects in mice did not translate to significant clinical efficacy in human trials.

3. 3

   preclinical

   AOD9604 Stimulates Proteoglycan Production in Cartilage Explants

   Stanton AS, Handelsman DJ, et al. (2013). Journal of Orthopaedic Research

   Key findings: AOD-9604 stimulated proteoglycan synthesis in bovine and human cartilage explants, suggesting potential for cartilage repair applications.

   Limitations: Ex vivo explant study. No in vivo cartilage repair data in humans.